Public verdict · Technology · NYSE

Salesforce, Inc. (CRM)

Monsaic grades Salesforce, Inc. (CRM) BUY, medium conviction, as of 2026-06-20. Salesforce is now a low-multiple, high-FCF, mature SaaS compounder under pressure from AI-disruption fears, slower organic growth, and a controversial debt-funded buyback. The stock is cheap enough to own, but the thesis requires proof that Agentforce/Data 360 can reaccelerate organic growth rather than merely rebrand the core platform.

BUYMedium conviction
Analysis as of · last full analysis
1 of 5 thesis-breakers shown · 6 claim-level citations · 4 valuation scenarios with probabilities · 15 sections — in the full report.

The one risk that matters

EPS compresses toward $12.50 and the multiple falls to 10x because AI agents pressure seat expansion, Marketing/Commerce remains weak, and investors penalize the debt-funded ASR.

Monsaic would change its verdict if

FY27 cRPO growth falls below 10% without a clear FX or timing explanation.

One of 5 kill criteria stated before the verdict was graded.

Last full analysis: . This page is a free excerpt and shows no market data; the full report states the price its analysis was built on and when it was observed.

This is the free excerpt of a 15-section Monsaic.

The full Monsaic carries the scenario math, the investigative grades, all 5 kill criteria, and every sourced claim behind this verdict — regenerated on demand.

Get the full Monsaic on CRM

What the full report covers

  1. 01Executive summary
  2. 02Fundamental analysis
  3. 03Balance sheet analysis
  4. 04Catalyst analysis
  5. 05Valuation & scenarios
  6. 06Comparative precedents
  7. 07Asymmetric risk profile
  8. 08Risk assessment
  9. 09Technical analysis
  10. 10Insider & institutional signals
  11. 11News sentiment
  12. 12Management & governance
  13. 13Narrative vs. substance
  14. 14Dilution & shareholder value
  15. 15Revenue quality

FAQ

Should I buy CRM stock?

Monsaic’s research verdict on Salesforce, Inc. (CRM) is BUY with medium conviction, as of 2026-06-20. Whether you should buy depends on your own goals, horizon, and risk tolerance — this is educational research, not personalized investment advice.

What is Monsaic’s verdict on CRM?

Monsaic grades Salesforce, Inc. (CRM) BUY, medium conviction, as of 2026-06-20. The verdict comes from a fifteen-section analysis with 5 stated thesis-breakers and 6 claim-level citations, and it is educational research, not personalized investment advice.

When was Salesforce, Inc. last analyzed by Monsaic?

The most recent full Monsaic analysis of Salesforce, Inc. (CRM) was produced on June 20, 2026. Every report states its analysis date, and a fresh report can be generated on demand.

What would change Monsaic’s verdict on CRM?

FY27 cRPO growth falls below 10% without a clear FX or timing explanation. This is the first of 5 kill criteria the analysis states in advance — the checkable conditions under which the thesis would be considered broken.

What is the key risk for Salesforce, Inc.?

EPS compresses toward $12.50 and the multiple falls to 10x because AI agents pressure seat expansion, Marketing/Commerce remains weak, and investors penalize the debt-funded ASR.

Keep reading

Monsaic provides educational investment research and analysis. It does not provide personalized financial advice, investment recommendations, brokerage services, or trading execution. Investors should do their own research and consult a qualified financial advisor before making investment decisions.